BioSpace News Archive

ERYTECH Pharma, announced that the Lyon Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma.

Ravensburg, June 14, 2023: Vetter, one of the world’s leading Contract Development and Manufacturing Organizations (CDMO), is consistently pursuing improvements to its sustainability strategy.

Tobra Medical, a specialty medical device company focused on micro surgery, announced the product launch of Tobra FeatherFlow.

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that Chairman and CEO Shane J. Schaffer, Pharm D, has been invited to participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

Biora Therapeutics, Inc. announced the closing of its previously announced registered direct offering of an aggregate of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock and concurrent private placement of warrants to purchase up to 3,018,868 shares of common stock.

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that all items of business were approved at its virtual Annual General and Special Meeting of Shareholders.

Enzo Biochem, Inc., a pioneering biosciences and diagnostics company, filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the pricing of an underwritten public offering of common stock.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities observed.

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, announced that it recently launched a funding round of up to $10 million.